CMC information for gene therapy INDs addressed
This article was originally published in The Gold Sheet
Executive SummaryFDA issued a final guideline on April 9 specifying the type of CMC information to be included in investigational new drug applications (INDs) for gene therapy products. The guidance specifies the necessary sterility testing and microbiological testing to support INDs, and replaces a November 2004 draft. The guidance notes that "in order to deliver a safe and effective product, human gene therapies present many manufacturing challenges. Some of these challenges include the variability and complexity inherent in the components used to generate the final product, such as the source of cells, the potential for adventitious agent contamination, the need for aseptic processing, and in the case of ex vivo genetically modified cell therapies the inability to 'sterilize' the final product because it contains living cells.
You may also be interested in...
Lengthy safety registries, extensive premarket testing for replication competent retrovirus, and manufacturing submission advice likely; pending CBER documents informed by review and approval of Novartis' Kymriah, Kite's Yescarta, and Spark's Luxturna.
Amneal has become the first company to secure US approval for, and to launch, a generic alternative to Merck & Co’s top-selling, off-patent NuvaRing contraceptive device in the US. Other generics developers appear to be several months behind.